Keyword: Taltz

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.

Johnson & Johnson is chasing giants in its play for psoriatic arthritis with Tremfya. Strong data could help the newcomer convince the FDA.

Besting AbbVie's megablockbuster Humira is no laughing matter, but now Eli Lilly's Taltz has doubled up on head-to-head wins.

Cosentyx has been battling it out with Taltz in psoriatic arthritis. But Lilly’s drug has a big win under its belt that Novartis can't tout.

Lilly is facing off against new competition and dealing with lower pricing in the U.S., but key drug classes are continuing to expand, its CEO said.

Eli Lilly is busy hounding Novartis’ Cosentyx with IL-17A med Taltz. In the meantime, Taltz will settle for besting an IL-23 competitor in psoriasis.

Novartis is gunning for an OK for Cosentyx in non-radiographic axial spondyloarthritis, and it’s now got one-year data to make its case to the FDA.

Novartis’ Cosentyx is battling Lilly’s Taltz in three indications. Now, with new phase 3 data in spondyloarthritis, Novartis wants to make it four. 

Eli Lilly’s Taltz is cruising toward blockbuster territory, and now it has a new indication to help it get there.

In December, J&J touted head-to-head results for Tremfya against Novartis’ Cosentyx. But now, Lilly has topped Tremfya in a contest of its own.